VEGFA and neoplasm: However, current anti-angiogenic therapy that primarily targets VEGF/VEGFR-2 has encountered difficulties and failures in treating most malignant solid tumors, including GBM17–21, likely due to insufficient eradication and functional inhibition of tumor-associated ECs.